Among patients with chronic kidney disease, NOACs presented a more favorable safety and efficacy profile compared to warfarin, reducing the risk of stroke or systemic embolism (RR 0.84; 95% CI 0.73-0.96).
Do NOACs improve efficacy and safety compared to warfarin in patients with chronic kidney disease?
NOACs present a more favorable safety and efficacy profile than warfarin in patients with chronic kidney disease.
Effect estimate: RR 0.84 (95% CI 0.73-0.96)
OBJECTIVE: Data regarding the efficacy and safety of warfarin and non-vitamin K antagonist oral anticoagulant (NOAC) among patients with chronic kidney disease (CKD) remain scarce. METHODS: ), stroke or systemic embolism, mortality, and major bleeding events. CKD was defined based on creatinine clearance (CrCl) ranging from mild (CrCl: 60-89 mL/min), moderate (CrCl: 30-59 mL/min), to severe (CrCl: 15-29 mL/min). RESULTS: (RR = 0.84; 95% CI 0.73-0.96), mortality (RR = 0.84; 95% CI 0.70-1.00), ICH (RR = 0.45; 95% CI 0.24-0.85), and major bleeding (RR = 0.76; 95% CI 0.64-0.91). CONCLUSIONS: Among patients with CKD treated with oral anticoagulants, NOACs present with a more favorable safety and efficacy profile for various cardiovascular outcomes.
Malhotra et al. (Thu,) conducted a other in chronic kidney disease (CKD). non-vitamin K antagonist oral anticoagulant (NOAC) vs. warfarin was evaluated on stroke or systemic embolism (RR 0.84, 95% CI 0.73-0.96). Among patients with chronic kidney disease, NOACs presented a more favorable safety and efficacy profile compared to warfarin, reducing the risk of stroke or systemic embolism (RR 0.84; 95% CI 0.73-0.96).